Charles River Labs (CRL) CEVP sells 5,046 shares under 10b5-1 plan
Rhea-AI Filing Summary
Charles River Laboratories International, Inc. executive Shannon M. Parisotto, CEVP of Discovery & Safety Assessment, reported a sale of 5,046 shares of common stock at $263.00 per share on August 5, 2026, under a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. Following the sale, Parisotto directly holds 4,807 shares, and also reports indirect ownership of 9,680 shares held by a trust and 28,510 shares held through Karpathos Investments LLC.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Net Seller: 5,046 shares
Net Sell
3 txns
Insider
Parisotto Shannon M
Role
CEVP, Disc & Safety Assessment
Sold
5,046 shs ($1.33M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 5,046 | $263.00 | $1.33M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 4,807 shares (Direct);
Common Stock — 9,680 shares (Indirect, By Trust);
Common Stock — 28,510 shares (Indirect, by Karpathos Investments LLC)
Footnotes (1)
- F1. This sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 4, 2026.
Key Figures
Shares Sold: 5,046 shares
Sale Price: $263.00 per share
Direct Holdings After Sale: 4,807 shares
+3 more
6 metrics
Shares Sold
5,046 shares
Common Stock sale on August 5, 2026
Sale Price
$263.00 per share
Price for the 5,046 Common Stock shares sold
Direct Holdings After Sale
4,807 shares
Total direct Common Stock shares following the transaction
Indirect Holdings by Trust
9,680 shares
Indirect Common Stock ownership classified as “By Trust”
Indirect Holdings via Karpathos Investments LLC
28,510 shares
Indirect Common Stock ownership “by Karpathos Investments LLC”
Rule 10b5-1 Plan Adoption Date
March 4, 2026
Trading plan under which the reported sale occurred
Key Terms
Rule 10b5-1 Trading Plan, indirect ownership, By Trust, Sale in open market or private transaction
4 terms
Rule 10b5-1 Trading Plan regulatory
"This sale occurred pursuant to a Rule 10b5-1 Trading Plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
indirect ownership financial
"classified as indirect ownership with nature of ownership By Trust"
By Trust financial
"total_shares_following_transaction 9680.0000, nature_of_ownership By Trust"
Sale in open market or private transaction financial
"transaction_code_description Sale in open market or private transaction"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What are Shannon M. Parisotto’s remaining direct CRL holdings after this Form 4?
After the reported sale, Shannon M. Parisotto directly holds 4,807 shares of CHARLES RIVER LABORATORIES (CRL) common stock. This figure reflects the total direct shares following the transaction reported in the Form 4 filing.
Was the CRL stock sale by Shannon M. Parisotto made under a Rule 10b5-1 plan?
Yes. The Form 4 footnote states the sale occurred under a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. The filing’s Rule 10b5-1 checkbox is also affirmed as true for this transaction.
What role does Shannon M. Parisotto hold at CHARLES RIVER LABORATORIES (CRL)?
Shannon M. Parisotto is an officer of CHARLES RIVER LABORATORIES (CRL) with the title CEVP, Discovery & Safety Assessment. The reported Form 4 transaction involves common stock associated with this executive role.
What type of security was involved in Shannon M. Parisotto’s CRL transaction?
The transaction involved Common Stock of CHARLES RIVER LABORATORIES (CRL). It is categorized as a non-derivative security, with the sale of 5,046 shares at a reported price of $263.00 per share.